Subcutaneous inoculation position affects the immune environment in CT26 carcinomas

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• The CT26 colon carcinoma cell line is a standard model for studying IDO-1 inhibitors and immune checkpoint antibodies.
• Understanding factors influencing tumor microenvironment and treatment response is crucial for effective cancer therapy.

Purpose of the Study:

• To investigate the impact of subcutaneous inoculation location on CT26 tumor growth and immune factor expression in mice.
• To evaluate how inoculation site affects the efficacy of anti-PD-1 and anti-CTLA-4 therapies.

Main Methods:

• CT26 cells were inoculated in the right upper or lower flank of Balb/c mice.
• Tumor growth was monitored, and tumors were analyzed for immune cell subpopulations and immune factors using FACS.
• Mice received treatments including an IDO-1 inhibitor (INCB024360), anti-PD-1, anti-CTLA-4, or no treatment.

Main Results:

• In vitro, CT26 cells treated with INCB024360 showed consistent IC50 values and peak inhibitory rates.
• In vivo, tumor volumes and the anti-tumor effects of anti-PD-1 and anti-CTLA-4 differed significantly based on inoculation site.
• The upper flank site showed higher CD8+T cell and INF-γ populations but lower myeloid cell and regulatory T cell (Treg) populations compared to the lower flank.

Conclusions:

• Tumor inoculation location significantly influences the tumor microenvironment and the efficacy of immunotherapies like anti-PD-1 and anti-CTLA-4.
• CT26 tumors derived from the same cell line but different inoculation sites should be considered distinct models due to variations in immune cell composition and response.
• These findings highlight the importance of considering anatomical site in preclinical cancer models.